

Won Seog Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4981113/publications.pdf>

Version: 2024-02-01

496
papers

14,057
citations

31976

53
h-index

38395

95
g-index

585
all docs

585
docs citations

585
times ranked

13232
citing authors

#	ARTICLE	IF	CITATIONS
1	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL). <i>Cancer Research and Treatment</i> , 2023, 55, 304-313.	3.0	1
2	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum β_2 -Microglobulin to PINK. <i>Cancer Research and Treatment</i> , 2023, 55, 314-324.	3.0	3
3	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. <i>Cancer Research and Treatment</i> , 2023, 55, 291-303.	3.0	4
4	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
5	Older patients (aged ≥ 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	3.5	24
6	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	8.2	29
7	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
8	Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 307-316.	2.9	3
9	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
10	Promising clinical efficacy and acceptable safety profile of sequential 67 GEMOX and radiotherapy for localized ENKTL. <i>Hematological Oncology</i> , 2022, 40, 341-342.	1.7	2
11	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. <i>Journal of Cancer</i> , 2022, 13, 1388-1397.	2.5	4
12	Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 641-648.	2.4	2
13	CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. <i>Blood Advances</i> , 2022, 6, 6120-6130.	5.2	3
14	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
15	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	1.6	9
16	Asia subpopulation analysis from the phase III POLARIX trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 7558-7558.	1.6	0
17	A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 7563-7563.	1.6	5
18	Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 7522-7522.	1.6	4

#	ARTICLE	IF	CITATIONS
19	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. <i>American Journal of Hematology</i> , 2022, 97, 1159-1169.	4.1	4
20	Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e972-e980.	0.4	9
21	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	1.6	17
22	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
23	Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. <i>Journal of Cancer</i> , 2021, 12, 2488-2497.	2.5	3
24	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 25.	17.0	41
25	Realâ€world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
26	Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping. <i>Scientific Reports</i> , 2021, 11, 5879.	3.3	5
27	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	1.4	53
28	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 628807.	2.8	13
29	Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. <i>Scientific Reports</i> , 2021, 11, 9243.	3.3	3
30	Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications. <i>Antiviral Research</i> , 2021, 189, 105063.	4.1	4
31	Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 4241-4250.	1.9	3
32	Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. <i>Experimental Hematology and Oncology</i> , 2021, 10, 33.	5.0	21
33	EGFR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 10342.	3.3	4
34	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
35	Real-world data on the survival outcome of patients with newly diagnosed Waldenstr�m macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 668-678.	1.7	2
36	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	5.2	60

#	ARTICLE	IF	CITATIONS
37	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	4.6	83
38	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β_2 -microglobulin Levels. <i>Cancer Research and Treatment</i> , 2021, 53, 847-856.	3.0	9
39	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
40	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric $\text{CD}34^+$ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 737-749.	1.3	2
41	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. <i>Human Pathology</i> , 2021, 113, 9-19.	2.0	3
42	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. <i>Cancer Research and Treatment</i> , 2021, . .	3.0	5
43	Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. <i>Journal of Neuro-Oncology</i> , 2021, 154, 207-217.	2.9	4
44	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
45	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. <i>BMC Cancer</i> , 2021, 21, 972.	2.6	6
46	IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S406-S407.	0.4	0
47	Prognostic value of single nucleotide polymorphisms for extranodal natural killer/T-cell lymphoma: the identification of risk factors in the molecular era. <i>Cancer Communications</i> , 2021, 41, 1232-1233.	9.2	2
48	HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S371.	0.4	0
49	Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 7289-7297.	1.9	6
50	TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S411.	0.4	0
51	Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021, 39, 664-673.	1.7	8
52	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 82.	2.6	9
53	Prognostic significance of serum β_2 -microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2021, , 1-7.	1.3	4
54	Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 621-621.	1.4	2

#	ARTICLE	IF	CITATIONS
55	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2021, 138, 132-132.	1.4	15
56	A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma. <i>Blood</i> , 2021, 138, 4362-4362.	1.4	1
57	Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1376-1376.	1.4	3
58	498â€¦Evorpcept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01. , 2021, 9, A530-A530.		4
59	Comprehensive Understanding of Gut Microbiota in Treatment Na ⁺ -ve Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2021, 138, 2409-2409.	1.4	1
60	Evorpcept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1740-1751.	10.7	46
61	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 200.	6.2	6
62	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged â‰¥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
63	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. <i>Modern Pathology</i> , 2020, 33, 603-615.	5.5	34
64	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43
65	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
66	Impact of fear of cancer recurrence on survival among lymphoma patients. <i>Psycho-Oncology</i> , 2020, 29, 364-372.	2.3	21
67	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkinâ€™s lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
68	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. <i>Lancet Oncology</i> , The, 2020, 21, 306-316.	10.7	49
69	Longâ€term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2â€year followâ€up of the CHRONOSâ€1 study. <i>American Journal of Hematology</i> , 2020, 95, 362-371.	4.1	102
70	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	5.2	3
71	Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3548.	3.7	12
72	Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. <i>Blood</i> , 2020, 136, 2754-2763.	1.4	74

#	ARTICLE	IF	CITATIONS
73	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	7.2	42
74	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
75	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. <i>Transplant International</i> , 2020, 33, 1211-1219.	1.6	3
76	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
77	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	17.0	17
78	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020, 103, 1630-1636.	2.2	6
79	Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. <i>Cytokine</i> , 2020, 129, 155048.	3.2	8
80	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2020, 136, 2548-2556.	1.4	17
81	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
82	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 120.	2.6	27
83	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , 2020, 34, 2243-2248.	7.2	35
84	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. <i>Annals of Hematology</i> , 2020, 99, 1283-1291.	1.8	8
85	Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. <i>Annals of Hematology</i> , 2020, 99, 1293-1302.	1.8	15
86	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	1.4	86
87	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. <i>Blood Advances</i> , 2020, 4, 868-879.	5.2	14
88	A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. <i>Annals of Hematology</i> , 2020, 99, 2095-2104.	1.8	24
89	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 731-740.	1.2	7
90	A Phase 1 Study of the Combination of MG4101, Ex Vivo-Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	1.4	8

#	ARTICLE	IF	CITATIONS
91	The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-5.	1.4	11
92	Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 32-33.	1.4	20
93	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
94	Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	1.4	7
95	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 946-956.	1.7	8
96	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	3.0	26
97	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. <i>Blood Research</i> , 2020, 55, 85-90.	1.3	3
98	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 194-204.	1.7	1
99	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2020, 136, 27-28.	1.4	1
100	404...ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). , 2020, , .		0
101	Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 317-325.	1.3	12
102	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7
103	Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. <i>BMC Cancer</i> , 2019, 19, 936.	2.6	34
104	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	2.6	17
105	Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
106	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	1.8	43
107	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	1.3	4
108	Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. <i>Leukemia and Lymphoma</i> , 2019, 60, 2237-2246.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016. <i>Medicine (United States)</i> , 2019, 98, e17641.	1.0	7
110	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12
111	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large-B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.4	2
112	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , 2019, 133, 137-146.	1.4	88
113	Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. <i>Cytokine</i> , 2019, 113, 371-379.	3.2	11
114	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	1.8	11
115	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
116	A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1953-1953.	1.4	15
117	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10
118	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq0 0 0 rgBT /Overlock 1 4728-4728.	1.4	3
119	Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. <i>Blood</i> , 2019, 134, 4009-4009.	1.4	8
120	Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 547-555.	3.0	9
121	Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas. <i>Cancer Research and Treatment</i> , 2019, 51, 611-622.	3.0	66
122	Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1302-1312.	3.0	6
123	Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study. <i>Blood</i> , 2019, 134, 4076-4076.	1.4	0
124	A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4030-4030.	1.4	0
125	Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404). <i>Blood</i> , 2019, 134, 2844-2844.	1.4	2
126	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. <i>Blood</i> , 2019, 134, 2847-2847.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma. <i>Blood</i> , 2019, 134, 1491-1491.	1.4	0
128	CXCR4 can induce PI3KÎ inhibitor resistance in ABC DLBCL. <i>Blood Cancer Journal</i> , 2018, 8, 23.	6.2	14
129	Aggressive natural killer-cell leukemiaÂmutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	12.8	107
130	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	1.8	16
131	Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1427-1436.	1.8	10
132	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976.	2.4	14
133	Early disease progression in patients with localized natural killer/Tâ€cell lymphoma treated with concurrent chemoradiotherapy. <i>Cancer Science</i> , 2018, 109, 2056-2062.	3.9	18
134	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	3.5	90
135	Use of complementary and alternative medicine by lymphoma survivors in South Korea. <i>European Journal of Oncology Nursing</i> , 2018, 33, 91-96.	2.1	11
136	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	2.6	5
137	Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay. <i>Human Pathology</i> , 2018, 73, 51-58.	2.0	5
138	Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky038.	2.9	12
139	Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma. <i>Cancer Research and Treatment</i> , 2018, 50, 575-581.	3.0	19
140	Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 140.	17.0	43
141	Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/Tâ€cell lymphoma. <i>Cancer Science</i> , 2018, 109, 3971-3980.	3.9	16
142	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. <i>Modern Pathology</i> , 2018, 31, 1418-1428.	5.5	33
143	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. <i>Annals of Hematology</i> , 2018, 97, 1851-1857.	1.8	5
144	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	1.8	13

#	ARTICLE	IF	CITATIONS
145	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2274-2284.	6.4	8
146	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
147	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	1.4	3
148	Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial. <i>Blood</i> , 2018, 132, 2921-2921.	1.4	2
149	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 1618-1618.	1.4	10
150	Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1595-1595.	1.4	10
151	Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study. <i>Blood</i> , 2018, 132, 395-395.	1.4	4
152	Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1613-1613.	1.4	1
153	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
154	Validation of the Korean Version of the Quality of Life“Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors. <i>Cancer Research and Treatment</i> , 2018, 50, 204-211.	3.0	14
155	Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1051-1063.	3.0	20
156	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2603-TPS2603.	1.6	1
157	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 7552-7552.	1.6	0
158	Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study. <i>Blood</i> , 2018, 132, 3718-3718.	1.4	0
159	Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 1657-1657.	1.4	2
160	Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. <i>Blood</i> , 2018, 132, 1596-1596.	1.4	1
161	Pitfalls and major issues in the histologic diagnosis of peripheral Tâ€cell lymphomas: results of the central review of 573 cases from the Tâ€Cell Project, an international, cooperative study. <i>Hematological Oncology</i> , 2017, 35, 630-636.	1.7	19
162	Macrophage inflammatory protein 1 alpha (MIP-1Î±) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 310-316.	1.7	14

#	ARTICLE	IF	CITATIONS
163	Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. <i>Haematologica</i> , 2017, 102, 903-909.	3.5	64
164	Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. <i>Future Oncology</i> , 2017, 13, 17-29.	2.4	10
165	Clinical development of CT-P10 and other biosimilar cancer therapeutics. <i>Future Oncology</i> , 2017, 13, 31-44.	2.4	6
166	Atypical presentations of MERS-CoV infection in immunocompromised hosts. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 769-773.	1.7	36
167	Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	1.7	23
168	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373.	4.6	70
169	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	3.5	41
170	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017, 36, 67-71.	2.4	20
171	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 995-1001.	1.3	5
172	Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. <i>Blood Cancer Journal</i> , 2017, 7, 653.	6.2	7
173	Brentuximab vedotin: clinical updates and practical guidance. <i>Blood Research</i> , 2017, 52, 243.	1.3	36
174	Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. <i>Blood Research</i> , 2017, 52, 193.	1.3	6
175	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. <i>Oncotarget</i> , 2017, 8, 17038-17049.	1.8	55
176	The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective. <i>Blood Research</i> , 2017, 52, 3.	1.3	2
177	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2017, 8, 1018-1024.	2.5	14
178	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3898-3905.	1.6	320
179	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
180	Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. <i>Oncotarget</i> , 2017, 8, 22014-22022.	1.8	40

#	ARTICLE	IF	CITATIONS
181	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7532-7532.	1.6	2
182	Copanlisib in patients with relapsed or refractory follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7535-7535.	1.6	5
183	Recent advances in understanding and managing T-cell lymphoma. F1000Research, 2017, 6, 2123.	1.6	4
184	FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 2466-2476.	1.8	21
185	Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF- κ B and Btk. Oncotarget, 2017, 8, 5361-5370.	1.8	22
186	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget, 2017, 8, 13782-13791.	1.8	17
187	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget, 2017, 8, 76231-76240.	1.8	23
188	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 92171-92182.	1.8	12
189	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. Korean Journal of Internal Medicine, 2017, 32, 890-899.	1.7	17
190	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. Cancer Research and Treatment, 2017, 49, 92-103.	3.0	4
191	Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Annals of Laboratory Medicine, 2016, 36, 209-214.	2.5	5
192	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	1.8	33
193	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Research, 2016, 5, 1933.	1.6	8
194	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Research, 2016, 51, 181.	1.3	11
195	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. Journal of Infection, 2016, 73, 496-505.	3.3	34
196	Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. International Journal of Hematology, 2016, 104, 591-595.	1.6	14
197	Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. Acta Haematologica, 2016, 136, 186-190.	1.4	6
198	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemotherapy and Pharmacology, 2016, 77, 865-873.	2.3	10

#	ARTICLE	IF	CITATIONS
199	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. <i>Haematologica</i> , 2016, 101, 757-763.	3.5	75
200	L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 41.	17.0	28
201	Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. <i>Annals of Hematology</i> , 2016, 95, 581-591.	1.8	11
202	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016, 95, 325-335.	1.8	36
203	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
204	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
205	Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 197-202.	0.4	4
206	CD79B limits response of diffuse large B cell lymphoma to ibrutinib. <i>Leukemia and Lymphoma</i> , 2016, 57, 1413-1422.	1.3	37
207	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
208	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016, 128, 1807-1807.	1.4	11
209	The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1820-1820.	1.4	19
210	Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate. <i>Blood</i> , 2016, 128, 4149-4149.	1.4	5
211	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
212	Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). <i>Blood</i> , 2016, 128, 470-470.	1.4	25
213	Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. <i>Oncotarget</i> , 2016, 7, 59892-59901.	1.8	18
214	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). <i>Oncotarget</i> , 2016, 7, 85584-85591.	1.8	36
215	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
216	Clonal relationships in recurrent B-cell lymphomas. <i>Oncotarget</i> , 2016, 7, 12359-12371.	1.8	17

#	ARTICLE	IF	CITATIONS
217	Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 560-569.	1.7	2
218	Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. <i>Cancer Research and Treatment</i> , 2016, 48, 312-321.	3.0	29
219	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921.	1.4	0
220	A Prognostic Index for Extranodal Natural Killer/T Cell Lymphoma after Non-Anthracycline-Based Treatment (PINK-B): Prognostic Index of Natural Killer Cell Lymphoma (PINK) Combined with Serum Beta-2 Microglobulin. <i>Blood</i> , 2016, 128, 1821-1821.	1.4	3
221	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. <i>Blood</i> , 2016, 128, 1823-1823.	1.4	0
222	Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL). <i>Blood</i> , 2016, 128, 3466-3466.	1.4	0
223	A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. <i>Haematologica</i> , 2015, 100, e505-e507.	3.5	43
224	The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 49.	17.0	33
225	Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvement. <i>Apmis</i> , 2015, 123, 990-992.	2.0	4
226	Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. <i>International Forum of Allergy and Rhinology</i> , 2015, 5, 960-966.	2.8	2
227	Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 383-396.	2.8	48
228	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
229	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 392-398.	2.4	19
230	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15
231	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. <i>Blood Research</i> , 2015, 50, 254.	1.3	60
232	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015, 6, 42803-42812.	1.8	23
233	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. <i>Oncotarget</i> , 2015, 6, 17764-17776.	1.8	136
234	Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. <i>Haematologica</i> , 2015, 100, e106-e109.	3.5	11

#	ARTICLE	IF	CITATIONS
235	Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. <i>International Journal of Hematology</i> , 2015, 101, 273-278.	1.6	8
236	Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2015, 106, 186-193.	3.9	26
237	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. <i>Lancet Haematology</i> , the, 2015, 2, e66-e74.	4.6	85
238	Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 179-182.	1.4	7
239	Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. <i>Acta Neurochirurgica</i> , 2015, 157, 569-576.	1.7	34
240	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , the, 2015, 2, e326-e333.	4.6	50
241	Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 677-683.	0.8	28
242	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
243	PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 194-201.	1.3	3
244	Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
245	Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. <i>Annals of Hematology</i> , 2015, 94, 1845-1851.	1.8	41
246	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. <i>International Journal of Hematology</i> , 2015, 102, 420-425.	1.6	3
247	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. <i>International Journal of Hematology</i> , 2015, 102, 678-688.	1.6	6
248	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015, 76, 636-643.	2.4	11
249	A subset of CD45+/CD19 ^{hi} cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3052-3057.	1.3	5
250	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	2.6	27
251	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> . 2015, 56, 1020-1026.	1.3	30
252	Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. <i>Annals of Hematology</i> , 2015, 94, 71-78.	1.8	58

#	ARTICLE	IF	CITATIONS
253	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 1493-1493.	1.4	5
254	Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study. <i>Blood</i> , 2015, 126, 256-256.	1.4	2
255	Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2015, 126, 5111-5111.	1.4	4
256	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	1.6	4
257	Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 448-457.	3.0	14
258	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
259	Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2015, 126, 3942-3942.	1.4	0
260	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2015, 126, 1904-1904.	1.4	0
261	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2015, 126, 5160-5160.	1.4	0
262	Prevalence and Prognostic Impact of CD30 and EBV Co-Expression in Korean Patients with EBV-Positive DLBCL of the Elderly. <i>Blood</i> , 2015, 126, 5021-5021.	1.4	0
263	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. <i>Blood</i> , 2015, 126, 700-700.	1.4	0
264	The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. <i>Anticancer Research</i> , 2015, 35, 2465-74.	1.1	13
265	Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. <i>Anticancer Research</i> , 2015, 35, 3333-40.	1.1	13
266	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. <i>OncoTargets and Therapy</i> , 2014, 7, 1717.	2.0	12
267	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	1.3	16
268	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	18
269	A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 768-776.	2.5	104
270	Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. <i>Nutrition and Cancer</i> , 2014, 66, 225-233.	2.0	47

#	ARTICLE	IF	CITATIONS
271	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. <i>Acta Haematologica</i> , 2014, 131, 18-27.	1.4	17
272	Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP. <i>Acta Haematologica</i> , 2014, 131, 156-161.	1.4	11
273	Indolent CD56-Positive Clonal T-Cell Lymphoproliferative Disease of the Stomach Mimicking Lymphomatoid Gastropathy. <i>Korean Journal of Pathology</i> , 2014, 48, 430-433.	1.3	2
274	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	1.4	23
275	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. <i>Annals of Hematology</i> , 2014, 93, 437-447.	1.8	19
276	DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. <i>Annals of Hematology</i> , 2014, 93, 99-105.	1.8	29
277	Dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2196-2198.	1.3	3
278	A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 371-375.	21.4	326
279	Health-related quality of life in Korean lymphoma survivors compared with the general population. <i>Annals of Hematology</i> , 2014, 93, 1531-1540.	1.8	16
280	Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. <i>Annals of Hematology</i> , 2014, 93, 1895-1901.	1.8	115
281	CD79B and MYD88 mutations in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 556-564.	2.0	43
282	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	1.4	10
283	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4443-4443.	1.4	5
284	A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL). <i>Blood</i> , 2014, 124, 503-503.	1.4	12
285	A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 5465-5465.	1.4	2
286	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8613-TPS8613.	1.6	4
287	Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 352.	1.7	27
288	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	1.6	1

#	ARTICLE	IF	CITATIONS
289	Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4421-4421.	1.4	0
290	Clinical Relevance of CD45+/CD19- Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center Experience. <i>Blood</i> , 2014, 124, 1622-1622.	1.4	0
291	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014, 34, 4299-306.	1.1	10
292	Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 98, 346-354.	1.6	35
293	Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. <i>International Journal of Hematology</i> , 2013, 97, 403-408.	1.6	19
294	Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 635-644.	1.8	20
295	Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 945-953.	2.3	33
296	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. <i>Investigational New Drugs</i> , 2013, 31, 1514-1521.	2.6	9
297	Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 86.	17.0	67
298	Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. <i>Investigational New Drugs</i> , 2013, 31, 469-472.	2.6	51
299	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
300	Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 2013, 129, 10-17.	1.4	18
301	EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. <i>Korean Journal of Pathology</i> , 2013, 47, 137.	1.3	42
302	Primary cardiac lymphoma mimicking infiltrative cardiomyopathy. <i>European Journal of Heart Failure</i> , 2013, 15, 589-591.	7.1	11
303	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2103-2109.	1.6	149
304	Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2035-2040.	1.3	37
305	Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 6062.	3.3	15
306	Plerixafor use for peripheral blood stem cell mobilization in Korea. <i>Blood Research</i> , 2013, 48, 72.	1.3	5

#	ARTICLE	IF	CITATIONS
307	Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. <i>Blood Research</i> , 2013, 48, 115.	1.3	5
308	Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. <i>Blood Research</i> , 2013, 48, 171.	1.3	14
309	Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2013, 122, 3037-3037.	1.4	2
310	Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8612-TPS8612.	1.6	1
311	ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8616-TPS8616.	1.6	6
312	Clinical Characteristics and Outcomes Of Waldeyerâ€™s Ring Lymphoma: Nation-Wide Study In Korea. <i>Blood</i> , 2013, 122, 4332-4332.	1.4	0
313	Weekly Four Times Rituximab Consolidation Following Reduced Cycles Of R-CHOP Induction Chemotherapy In Extremely Elderly Patients With Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013, 122, 3031-3031.	1.4	0
314	Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP Chemotherapy. <i>Blood</i> , 2013, 122, 5103-5103.	1.4	0
315	Reply to A. Chan et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1016-1017.	1.6	4
316	Epsteinâ€™Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. <i>Leukemia and Lymphoma</i> , 2012, 53, 1586-1591.	1.3	55
317	Endoscopic Findings in Mantle Cell Lymphoma with Gastrointestinal Tract Involvement. <i>Acta Haematologica</i> , 2012, 127, 129-134.	1.4	13
318	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	1.3	11
319	Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease â€™ Consortium for Improving Survival of Lymphoma Study. <i>Acta Haematologica</i> , 2012, 127, 100-104.	1.4	16
320	DeSUMOylating isopeptidase: a second class of SUMO protease. <i>EMBO Reports</i> , 2012, 13, 339-346.	4.5	153
321	¹¹ C-Methionine PET/CT and MRI of Primary Central Nervous System Diffuse Large B-cell Lymphoma Before and After High-Dose Methotrexate. <i>Clinical Nuclear Medicine</i> , 2012, 37, e241-e244.	1.3	18
322	Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2012, 53, 1515-1524.	1.3	32
323	Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. <i>Leukemia and Lymphoma</i> , 2012, 53, 173-175.	1.3	11
324	Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population. <i>Thrombosis Research</i> , 2012, 130, e6-e12.	1.7	48

#	ARTICLE	IF	CITATIONS
325	Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. <i>Leukemia Research</i> , 2012, 36, 1172-1178.	0.8	14
326	Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637.	1.6	5
327	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. <i>Annals of Hematology</i> , 2012, 91, 1747-1756.	1.8	14
328	A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. <i>The Korean Journal of Hematology</i> , 2012, 47, 53.	0.7	12
329	Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?. <i>The Korean Journal of Hematology</i> , 2012, 47, 202.	0.7	8
330	Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	5.1	47
331	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	4.1	134
332	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 937-940.	4.1	40
333	Aggressive natural killer cell leukemia: Therapeutic potential of asparaginase and allogeneic hematopoietic stem cell transplantation. <i>Cancer Science</i> , 2012, 103, 1079-1083.	3.9	67
334	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233.	1.8	11
335	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551.	1.8	50
336	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	2.6	17
337	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8023-8023.	1.6	2
338	A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8029-8029.	1.6	0
339	The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort Study. <i>Blood</i> , 2012, 120, 5095-5095.	1.4	0
340	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.. <i>Blood</i> , 2012, 120, 2683-2683.	1.4	0
341	Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. <i>Blood</i> , 2012, 120, 3669-3669.	1.4	0
342	The Impact of Activated Akt Expression On Clinical Outcome in Diffuse Large B-Cell Lymphoma: A Clinicopathological Study of 99 Cases.. <i>Blood</i> , 2012, 120, 2676-2676.	1.4	1

#	ARTICLE	IF	CITATIONS
343	Extranodal NK/T-cell lymphoma presented as panniculitis of breast in a male patient: A case report. <i>European Journal of Radiology Extra</i> , 2011, 78, e105-e107.	0.1	0
344	Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1630-1637.	2.0	32
345	Frontal Sinus Lymphoma Presenting As Progressive Multiple Cranial Nerve Palsy. <i>Yonsei Medical Journal</i> , 2011, 52, 1044.	2.2	9
346	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	1.4	121
347	Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. <i>Blood</i> , 2011, 117, 1291-1300.	1.4	94
348	Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2011, 29, 154-160.	2.6	11
349	Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 495-502.	2.8	13
350	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	1.8	26
351	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , 2011, 90, 1391-1398.	1.8	49
352	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 1409-1418.	1.8	7
353	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	1.6	21
354	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 317-320.	1.3	3
355	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4410-4416.	1.6	532
356	Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas. <i>Blood</i> , 2011, 118, 1642-1642.	1.4	2
357	Primary Gastrointestinal Follicular Lymphoma: Single-Center 12 Year Experiences. <i>Hepato-Gastroenterology</i> , 2011, 59, 751-3.	0.5	1
358	Stage I or II Marginal Zone B-Cell Lymphoma; Multicenter Retrospective Analysis of 217 Cases. <i>Blood</i> , 2011, 118, 5219-5219.	1.4	0
359	Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including <i>Campylobacter Jejuni</i> . <i>Blood</i> , 2011, 118, 5224-5224.	1.4	0
360	Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea. <i>Blood</i> , 2011, 118, 2021-2021.	1.4	0

#	ARTICLE	IF	CITATIONS
361	Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC. Blood, 2011, 118, 3563-3563.	1.4	0
362	Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study. Blood, 2011, 118, 1595-1595.	1.4	0
363	¹⁸ F-CD20 uptake and its clinical relevance in primary gastric lymphoma. Hematological Oncology, 2010, 28, 57-61.	1.7	36
364	Primary Cutaneous Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder-2 Cases With Unusual, Prolonged Clinical Course. American Journal of Dermatopathology, 2010, 32, 832-836.	0.6	21
365	Pulmonary marginal zone B-cell lymphoma of MALT type: What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. Annals of Hematology, 2010, 89, 563-568.	1.8	54
366	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. Annals of Hematology, 2010, 89, 1011-1018.	1.8	10
367	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. International Journal of Hematology, 2010, 91, 456-463.	1.6	22
368	A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2010, 91, 886-891.	1.6	11
369	Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. International Journal of Hematology, 2010, 92, 510-517.	1.6	13
370	Treatment of localized extranodal NK/T cell lymphoma, nasal type. International Journal of Hematology, 2010, 92, 690-696.	1.6	50
371	Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Investigational New Drugs, 2010, 28, 171-177.	2.6	10
372	Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Investigational New Drugs, 2010, 28, 516-522.	2.6	15
373	Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cellular Signalling, 2010, 22, 1858-1863.	3.6	16
374	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leukemia Research, 2010, 34, 1175-1179.	0.8	24
375	Stage IV marginal zone B-cell lymphoma: prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Science, 2010, 101, 2443-2447.	3.9	8
376	Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. Experimental and Therapeutic Medicine, 2010, 1, 943-946.	1.8	2
377	Hodgkin's Lymphoma Arising in a Patient With Hypersensitivity to Mosquito Bites: A Case Report. Journal of Clinical Oncology, 2010, 28, e148-e150.	1.6	10
378	Reply to K. Shimada et al. Journal of Clinical Oncology, 2010, 28, e230-e230.	1.6	1

#	ARTICLE	IF	CITATIONS
379	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	1.4	15
380	Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 289-296.	1.2	90
381	Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 157-163.	1.6	15
382	Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study.. <i>Blood</i> , 2010, 116, 1790-1790.	1.4	1
383	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.. <i>Blood</i> , 2010, 116, 1791-1791.	1.4	2
384	Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study. <i>Blood</i> , 2010, 116, 2873-2873.	1.4	2
385	Side Population Cells of Human B-Cell Non-Hodgkin Lymphoma Cell Lines May Contain Lymphoma-Stem Cells Responsible for Lymphoma Initiation. <i>Blood</i> , 2010, 116, 3105-3105.	1.4	0
386	Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients.. <i>Blood</i> , 2010, 116, 4494-4494.	1.4	0
387	Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 387 T B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.. <i>Blood</i> , 2010, 116, 1786-1786.	1.4	0
388	Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 T <i>Blood</i> , 2010, 116, 1765-1765.	1.4	0
389	Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -. <i>Blood</i> , 2010, 116, 3091-3091.	1.4	0
390	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. <i>Blood</i> , 2010, 116, 5084-5084.	1.4	0
391	Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. <i>Blood</i> . 2010. 116. 3536-3536.	1.4	1
392	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1110-1118.	1.3	7
393	Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6027-6032.	1.6	312
394	Depletion of <sc>l</sc>ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2009, 83, 108-118.	2.2	18
395	Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	4.1	10
396	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. <i>Medical Oncology</i> , 2009, 26, 45-48.	2.5	28

#	ARTICLE	IF	CITATIONS
397	Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. <i>Medical Oncology</i> , 2009, 26, 186-192.	2.5	30
398	Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , 2009, 88, 111-119.	1.8	32
399	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. <i>Annals of Hematology</i> , 2009, 88, 639-645.	1.8	29
400	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , 2009, 88, 1099-1106.	1.8	21
401	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 27-33.	2.3	9
402	Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 748-751.	1.4	16
403	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. <i>Leukemia and Lymphoma</i> , 2009, 50, 1119-1125.	1.3	21
404	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	1.3	63
405	Prognostic significance of anatomic subsites: Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. <i>Radiotherapy and Oncology</i> , 2009, 90, 236-241.	0.6	49
406	Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 2688-2688.	1.4	26
407	Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.. <i>Blood</i> , 2009, 114, 5009-5009.	1.4	0
408	Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.. <i>Blood</i> , 2009, 114, 4999-4999.	1.4	0
409	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. <i>Blood</i> , 2009, 114, 5017-5017.	1.4	0
410	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
411	Excessive Toxicity of Once Daily Intravenous Busulfan, Melphalan, and Thiotepa Followed by Autologous Stem Cell Transplantation On Patients with Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 4361-4361.	1.4	9
412	Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. <i>Blood</i> , 2009, 114, 4992-4992.	1.4	0
413	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.. <i>Blood</i> , 2009, 114, 5024-5024.	1.4	7
414	Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 299-304.	2.3	5

#	ARTICLE	IF	CITATIONS
415	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	2.5	7
416	Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 155-163.	2.8	18
417	<i>CD20</i> is the target gene of chromosome band 6q23.3q24.1 loss in ocular adnexal marginal zone B cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1-7.	2.8	85
418	Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. <i>Cancer Science</i> , 2008, 99, 1016-1020.	3.9	193
419	Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. <i>European Journal of Haematology</i> , 2008, 81, 364-373.	2.2	44
420	Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1356-1364.	2.0	133
421	Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis?. <i>Acta Haematologica</i> , 2008, 120, 199-206.	1.4	31
422	SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. <i>Leukemia and Lymphoma</i> , 2008, 49, 1392-1398.	1.3	18
423	Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 88-94.	1.3	21
424	Outcomes of a Modified CALGB 19802 Regimen in Adult Acute Lymphoblastic Leukemia. <i>Journal of Korean Medical Science</i> , 2008, 23, 278.	2.5	1
425	Relapsed Intravascular Large B-cell Lymphoma in the Lungs. <i>The Korean Journal of Hematology</i> , 2008, 43, 113.	0.7	0
426	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. <i>Blood</i> , 2008, 112, 4219-4219.	1.4	0
427	Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma. <i>Blood</i> , 2008, 112, 3601-3601.	1.4	20
428	Alemtuzumab and DHAP (A-DHAP) Is An Effective Salvage Therapy for Peripheral T-Cell Lymphoma, Unspecified: Interim Results of a Phase II Prospective Multicenter Study. <i>Blood</i> , 2008, 112, 5002-5002.	1.4	0
429	Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?. <i>Blood</i> , 2008, 112, 2833-2833.	1.4	0
430	Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. <i>Clinical Cancer Research</i> , 2007, 13, 3250-3254.	7.0	48
431	Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 463-468.	2.0	47
432	Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007, 258, 90-97.	7.2	19

#	ARTICLE	IF	CITATIONS
433	Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Letters, 2007, 581, 623-628.	2.8	20
434	Paclitaxel with Cisplatin as Salvage Treatment for Patients with Previously Treated Advanced Transitional Cell Carcinoma of the Urothelial Tract. Neoplasia, 2007, 9, 18-22.	5.3	32
435	Postremission therapy for acute myeloid leukemia in the first remission. Leukemia and Lymphoma, 2007, 48, 937-943.	1.3	6
436	Quantifying the Circulating Epstein-Barr Virus (EBV) DNA to Monitor a Case of Aggressive Natural Killer Cell Leukemia. The Korean Journal of Hematology, 2007, 42, 167.	0.7	0
437	A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy. Journal of Korean Medical Science, 2007, 22, 758.	2.5	16
438	Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. American Journal of Hematology, 2007, 82, 446-452.	4.1	41
439	Consideration of aggressive therapeutic strategies for primary testicular lymphoma. American Journal of Hematology, 2007, 82, 840-845.	4.1	39
440	Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: Comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes and Cancer, 2007, 46, 776-783.	2.8	54
441	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leukemia Research, 2007, 31, 359-364.	0.8	41
442	What is stage II in high-grade primary gastric lymphoma?. Leukemia Research, 2007, 31, 1039-1043.	0.8	2
443	Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clinical Immunology, 2007, 125, 257-267.	3.2	64
444	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. European Journal of Haematology, 2007, 79, 287-291.	2.2	14
445	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Annals of Hematology, 2007, 86, 493-498.	1.8	137
446	The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.. Blood, 2007, 110, 1892-1892.	1.4	2
447	Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.. Blood, 2007, 110, 1914-1914.	1.4	1
448	A Phase I Trial of Bortezomib Plus CHOP Every 2 Weeks in Patients with Advanced Stage Diffuse Large B-Cell Lymphomas.. Blood, 2007, 110, 4446-4446.	1.4	2
449	Frequent CD7 Antigen Loss in Aggressive Natural Killer-Cell Leukemia Can Be a Useful Diagnostic Marker.. Blood, 2007, 110, 2400-2400.	1.4	0
450	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 3446-3446.	1.4	0

#	ARTICLE	IF	CITATIONS
451	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. Blood, 2007, 110, 1361-1361.	1.4	0
452	High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population. Leukemia and Lymphoma, 2006, 47, 2128-2131.	1.3	14
453	Pulmonary Complications After Hematopoietic Stem Cell Transplantation. Journal of Korean Medical Science, 2006, 21, 406.	2.5	29
454	Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome. Leukemia Research, 2006, 30, 1253-1258.	0.8	10
455	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Annals of Hematology, 2006, 85, 285-290.	1.8	19
456	Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Annals of Hematology, 2006, 85, 781-786.	1.8	43
457	Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2006, 57, 91-96.	2.3	35
458	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. Leukemia and Lymphoma, 2006, 47, 1253-1259.	1.3	18
459	Intestinal Marginal Zone B-Cell Lymphoma of MALT Type: Clinical Manifestation and Outcome of a Rare Disease.. Blood, 2006, 108, 4742-4742.	1.4	1
460	Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. Blood, 2006, 108, 4670-4670.	1.4	0
461	The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK/T-cell lymphoma. Haematologica, 2006, 91, 427-8.	3.5	32
462	Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. Oncology Reports, 2006, 15, 1541-9.	2.6	16
463	A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncology Reports, 2006, 16, 1117-21.	2.6	60
464	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. International Journal of Hematology, 2005, 81, 258-263.	1.6	6
465	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-14.	2.3	40
466	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 214-217.	1.3	6
467	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biology of Blood and Marrow Transplantation, 2005, 11, 122-128.	2.0	35
468	Curcumin inhibits interferon- γ induced NF- κ B and COX-2 in human A549 non-small cell lung cancer cells. Biochemical and Biophysical Research Communications, 2005, 334, 313-318.	2.1	56

#	ARTICLE	IF	CITATIONS
469	Primary Gastric T-Cell Lymphoma: Clinicopathologic Features and Treatment Outcome.. Blood, 2005, 106, 3355-3355.	1.4	0
470	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. Blood, 2005, 106, 1491-1491.	1.4	0
471	Prospective Clinical Study of Surgical Resection Followed by CHOP in Localized Intestinal Lymphoma.. Blood, 2005, 106, 4743-4743.	1.4	0
472	Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncology Reports, 2005, 13, 859-64.	2.6	54
473	The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation. Journal of Korean Medical Science, 2004, 19, 79.	2.5	2
474	Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. Leukemia and Lymphoma, 2004, 45, 339-344.	1.3	50
475	Primary Pulmonary Non-Hodgkin's Lymphoma. Japanese Journal of Clinical Oncology, 2004, 34, 510-514.	1.3	103
476	Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea. International Journal of Hematology, 2004, 79, 185-188.	1.6	36
477	Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2004, 54, 385-390.	2.3	83
478	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 477-480.	1.3	41
479	CHOP Followed by Radiotherapy for Localized Aggressive Primary Gastric Lymphoma: Results of a Multi Center Phase II Study.. Blood, 2004, 104, 3306-3306.	1.4	0
480	Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. Japanese Journal of Clinical Oncology, 2003, 33, 533-537.	1.3	195
481	Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2003, 33, 509-513.	1.3	5
482	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. Japanese Journal of Clinical Oncology, 2003, 33, 620-625.	1.3	3
483	Promoter methylation and down-regulation of DAPK is associated with gastric atrophy. International Journal of Molecular Medicine, 2003, 12, 827-30.	4.0	12
484	Docetaxel 75 mg/m ² is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. Japanese Journal of Clinical Oncology, 2002, 32, 248-254.	1.3	103
485	Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 354-357.	1.3	18
486	Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. American Journal of Hematology, 2002, 71, 75-79.	4.1	63

#	ARTICLE	IF	CITATIONS
487	Sexuality and Quality of Life after Hematopoietic Stem Cell Transplantation. Korean Journal of Internal Medicine, 2002, 17, 19-23.	1.7	11
488	Adenocarcinoma of Unknown Primary Site. Korean Journal of Internal Medicine, 2002, 17, 234-239.	1.7	6
489	Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica, 2002, 87, 1343-5.	3.5	48
490	Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma. Investigational New Drugs, 2001, 19, 81-83.	2.6	123
491	Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. Human Gene Therapy, 2001, 12, 671-684.	2.7	123
492	A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer. Cancer Research and Treatment, 2001, 33, 225-228.	3.0	0
493	Locoregional Response and Increased Natural Killer Activity after Intratumoral Injection of HLA-B7/IL-12-Microglobulin Gene in Patients with Cancer. Human Gene Therapy, 1998, 9, 2031-2038.	2.7	12
494	Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy. Experimental and Molecular Medicine, 1997, 29, 65-69.	7.7	11
495	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. Archives of Medical Science, 0, , .	0.9	0
496	Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. Annals of Hematology, 0, , .	1.8	2